Champions Oncology Reports $14 Million Revenue for Q1 FY 2026, Adjusted EBITDA at $60,000; Revenue Slightly Lower Than Last Year

Reuters09-16

<a href="https://laohu8.com/S/CSBR">Champions Oncology</a> Reports $14 Million Revenue for Q1 FY 2026, Adjusted EBITDA at $60,000; Revenue Slightly Lower Than Last Year

Champions Oncology Inc. reported its financial results for the first quarter of fiscal 2026, ending July 31, 2025. The company achieved total revenue of $14 million, marking a decrease from the previous year's first quarter, but showing sequential growth that met expectations. The company recorded an adjusted EBITDA of $59,000, down from $2.0 million in the first quarter of fiscal 2025. Champions reported a loss from operations of $527,000 compared to an income from operations of $1.3 million in the same period last year. David Miller, CFO of Champions Oncology, noted that the company anticipates continued topline expansion and margin improvement driven by a healthy services pipeline and growing demand for proprietary data offerings. The company also announced the appointment of Rob Brainin as Chief Executive Officer to lead the next phase of growth.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Champions Oncology Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1073466) on September 15, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2567426471?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-16 03:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2567426471","market":"us","top_or_hot":-1,"title":"Champions Oncology Reports $14 Million Revenue for Q1 FY 2026, Adjusted EBITDA at $60,000; Revenue Slightly Lower Than Last Year","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CSBR\">Champions Oncology</a> Reports $14 Million Revenue for Q1 FY 2026, Adjusted EBITDA at $60,000; Revenue Slightly Lower Than Last Year\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Champions Oncology Inc. reported its financial results for the first quarter of fiscal 2026, ending July 31, 2025. The company achieved total revenue of $14 million, marking a decrease from the previous year's first quarter, but showing sequential growth that met expectations. The company recorded an adjusted EBITDA of $59,000, down from $2.0 million in the first quarter of fiscal 2025. Champions reported a loss from operations of $527,000 compared to an income from operations of $1.3 million in the same period last year. David Miller, CFO of Champions Oncology, noted that the company anticipates continued topline expansion and margin improvement driven by a healthy services pipeline and growing demand for proprietary data offerings. The company also announced the appointment of Rob Brainin as Chief Executive Officer to lead the next phase of growth.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Champions Oncology Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1073466) on September 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Champions Oncology Reports $14 Million Revenue for Q1 FY 2026, Adjusted EBITDA at $60,000; Revenue Slightly Lower Than Last Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChampions Oncology Reports $14 Million Revenue for Q1 FY 2026, Adjusted EBITDA at $60,000; Revenue Slightly Lower Than Last Year\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-16 03:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CSBR\">Champions Oncology</a> Reports $14 Million Revenue for Q1 FY 2026, Adjusted EBITDA at $60,000; Revenue Slightly Lower Than Last Year\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Champions Oncology Inc. reported its financial results for the first quarter of fiscal 2026, ending July 31, 2025. The company achieved total revenue of $14 million, marking a decrease from the previous year's first quarter, but showing sequential growth that met expectations. The company recorded an adjusted EBITDA of $59,000, down from $2.0 million in the first quarter of fiscal 2025. Champions reported a loss from operations of $527,000 compared to an income from operations of $1.3 million in the same period last year. David Miller, CFO of Champions Oncology, noted that the company anticipates continued topline expansion and margin improvement driven by a healthy services pipeline and growing demand for proprietary data offerings. The company also announced the appointment of Rob Brainin as Chief Executive Officer to lead the next phase of growth.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Champions Oncology Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1073466) on September 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CSBR","symbol_name":"Champions Oncology, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250915:nNDLcgMh9k:1","article_id":"2567426471","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2567426471","pubTimestamp":1757966121,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Champions Oncology Reports $14 Million Revenue for Q1 FY 2026, Adjusted EBITDA at $60,000; Revenue Slightly Lower Than Last Year. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Champions Oncology Inc. published the original content used to generate this news brief via ACCESS Newswire  on September 15, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"CSBR":"Champions Oncology, Inc."},"translate_title":"Champions Oncology报告2026财年第一季度收入为1400万美元，调整后EBITDA为60,000美元；收入略低于去年","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CSBR":0.9},"content_text":"Champions Oncology Reports $14 Million Revenue for Q1 FY 2026, Adjusted EBITDA at $60,000; Revenue Slightly Lower Than Last Year\n    \n\n        Champions Oncology Inc. reported its financial results for the first quarter of fiscal 2026, ending July 31, 2025. The company achieved total revenue of $14 million, marking a decrease from the previous year's first quarter, but showing sequential growth that met expectations. The company recorded an adjusted EBITDA of $59,000, down from $2.0 million in the first quarter of fiscal 2025. Champions reported a loss from operations of $527,000 compared to an income from operations of $1.3 million in the same period last year. David Miller, CFO of Champions Oncology, noted that the company anticipates continued topline expansion and margin improvement driven by a healthy services pipeline and growing demand for proprietary data offerings. The company also announced the appointment of Rob Brainin as Chief Executive Officer to lead the next phase of growth.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Champions Oncology Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1073466) on September 15, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"executive,dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2567426471","isCrawlerRequest":true}